Clinical Trials Logo

Clinical Trial Summary

To preliminary assess the efficacy and safety of recombinant human growth hormone injection on the treatment of small for gestational age (SGA), and determine the best dose.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03221933
Study type Interventional
Source GeneScience Pharmaceuticals Co., Ltd.
Contact
Status Completed
Phase Phase 2
Start date December 2009

See also
  Status Clinical Trial Phase
Completed NCT05059093 - Developing and Testing AI Models for Fetal Biometry and Amniotic Volume Assessment in Fetal Ultrasound Scans.
Recruiting NCT02375620 - Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature Phase 2
Not yet recruiting NCT05043753 - "Fetal gRowth AbnorMality dEtection Trial" N/A
Not yet recruiting NCT05070234 - Genetic Diagnosis and Human Growth Hormone Treatment in Small for Gestational Age Children With Short Stature
Active, not recruiting NCT05343403 - Parental Participation on the Neonatal Ward - the neoPARTNER Study
Not yet recruiting NCT05436119 - Select Nutrient and Gene Variant Analysis in a Targeted Diet and Lifestyle Intervention Reduces Preterm Birth
Recruiting NCT04315545 - Pregnancy Outcomes and Maternal Insulin Sensitivity
Recruiting NCT03245333 - A Study of Recombinant Human Growth Hormone Injection for Short Children With Small for Small for Gestational Age(SGA) Phase 3
Not yet recruiting NCT04050488 - Zinc Supplementation on Very Low Birth Weight Infant Phase 4
Recruiting NCT05144035 - A Real World Study of the Effect of Early PEG-rhGH Therapy on Cognitive Development of SGA Infants Phase 4